1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen Delivers Mixed Data For Rocatinlimab In Atopic Dermatitis, Uplizna In Myasthenia Gravis

Four Of Seven More AD Trials To Read Out Over Next Year

 
• By Mandy Jackson

Rocatinlimab met its Phase III endpoints with results that appear uncompetitive with AD market leader Dupixent, while Uplizna may offer a compelling twice-yearly gMG treatment option.

Long Exposure Night Time Rocket Launch - Planet Earth with a spectacular sunset
HORIZON is the first of eight ROCKET studies in atopic dermatitis • Source: Shutterstock

Amgen, Inc. made an unusual move to release topline Phase III results for its Kyowa Kirin Co., Ltd.-partnered OX40 inhibitor rocatinlimab in atopic dermatitis (AD) and its CD19 inhibitor Uplizna (inebilizumab) in generalized myasthenia gravis (gMG), holding an analyst call after the stock market closed on 24 September and forgoing press releases. The clinical trials for both drugs delivered statistically significant results, but while most analysts saw a role for Uplizna in gMG, all questioned rocatinlimab’s ability to compete in AD.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

More from R&D

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.